James D. Watson, M.B.A.

Chief Business Officer & President, Sigilon Islet Cell Therapy (ICT)

Mr. Watson has over 25 years of experience working in the biopharmaceutical industry. Most recently, he was Chief Business Officer at Alvine Pharmaceuticals where he and his team put in place an option for acquisition by AbbVie and managed the Alvine/AbbVie alliance for over 2 years. Before his time at Alvine, Mr. Watson was Managing Director and Head of Private Equity at Burrill & Company. He also spent nearly 5 years as CEO of Burrill’s Merchant Banking Group, a role in which he advised numerous biopharmaceutical clients on strategic transactions. Prior to Burrill, Mr. Watson was SVP of Corporate Development and Marketing at Incyte and General Manager at Chemdex. He also served as Head of the San Francisco office of The Wilkerson Group. He began his career with Eli Lilly holding a variety of sales, marketing, and new product planning positions.

Mr. Watson holds a B.A. in Economics from Portsmouth University in England and a Fulbright Scholarship and M.B.A. from Indiana University.

‹ Back